Trial Profile
A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NABPLAGEMD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Paricalcitol (Primary) ; Cisplatin; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms NABPLAGEMD
- 13 Dec 2023 Status changed from active, no longer recruiting to completed.
- 11 Apr 2023 Planned End Date changed from 31 Dec 2023 to 31 Jan 2024.
- 11 Apr 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.